1. 1051. Rapid onset of seroprotection rates in young adults immunized with a tri-antigenic hepatitis B virus (HBV) vaccine compared to a mono-antigenic HBV vaccine. (31st December 2020) Authors: Vesikari, Timo; Langley, Joanne M; Machluf, Nathalie; Spaans, Johanna; Yassin-Rajkumar, Bebi; Anderson, Dave; Popovic, Vlad; Diaz-Mitoma, Francisco Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S555 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 8. Higher hepatitis B antibody titres induced in all adults vaccinated with a tri-antigenic hepatitis B (HBV) vaccine, compared to a mono-antigenic HBV vaccine: results from two pivotal phase 3 double-blind, randomized studies (PROTECT and CONSTANT). (31st December 2020) Authors: Langley, Joanne M; Vesikari, Timo; Machluf, Nathalie; Spaans, Johanna; Yassin-Rajkumar, Bebi; Anderson, Dave; Popovic, Vlad; Diaz-Mitoma, Francisco Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity. Issue 35 (16th August 2021) Authors: Fluckiger, Anne-Catherine; Ontsouka, Barthelemy; Bozic, Jasminka; Diress, Abebaw; Ahmed, Tanvir; Berthoud, Tamara; Tran, Anh; Duque, Diane; Liao, Mingmin; McCluskie, Michael; Diaz-Mitoma, Francisco; Anderson, David E.; Soare, Catalina Journal: Vaccine Issue: Volume 39:Issue 35(2021) Page Start: 4988 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Antimicrobial Susceptibility of Canadian Isolates of Helicobacter pylori in Northeastern Ontario. Issue 3 (2015) Authors: Eng, Nelson F; Ybazeta, Gustavo; Chapman, Katrina; Fraleigh, Nya L; Letto, Rebecca; Altman, Eleonora; Diaz-Mitoma, Francisco Journal: Canadian journal of infectious diseases & medical microbiology = Issue: Volume 26:Issue 3(2015) Page Start: 137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac®, compared with Engerix-B® in healthy Asian adults: A phase 3 randomized clinical trial. Issue 29 (29th June 2021) Authors: Diaz-Mitoma, Francisco; Popovic, Vlad; Spaans, Johanna N. Journal: Vaccine Issue: Volume 39:Issue 29(2021) Page Start: 3892 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. ATIM-14. CMV gB/pp65 eVLPs FORMULATED WITH GM-CSF AS A THERAPEUTIC VACCINE AGAINST RECURRENT GLIOBLASTOMA (GBM). (5th November 2018) Authors: Iwamoto, Fabio; Diaz-Mitoma, Francisco; Anderson, David; Lassman, Andrew B Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. ATIM-26. INTERIM RESULTS OF THE EXTENSION PHASE OF A PHASE I/IIA TRIAL OF A THERAPEUTIC CMV VACCINE AGAINST RECURRENT GLIOBLASTOMA (GBM). (11th November 2019) Authors: Wen, Patrick; Reardon, David; Lee, Eudocia; Iwamoto, Fabio; Anderson, David; Diaz-Mitoma, Francisco; Lassman, Andrew Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. CTIM-07. IDENTIFICATION OF A BASELINE BIOMARKER ASSOCIATED WITH TUMOR RESPONSES IN A PHASE I/IIa TRIAL OF A THERAPEUTIC CMV VACCINE AGAINST RECURRENT GLIOBLASTOMA (GBM). (9th November 2020) Authors: Wen, Patrick; Reardon, David; Forst, Deborah; Lee, Eudocia; Iwamoto, Fabio; Diaz-Mitoma, Francisco; Anderson, David; Lassman, Andrew Journal: Neuro-oncology Issue: Volume 22(2020)Supplement 2 Page Start: ii34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. CTIM-14. COMPREHENSIVE BIOMARKER ANALYSIS OF RESPONDERS AND NON-RESPONDERS IN A PHASE IIA TRIAL OF A CMV VACCINE IMMUNOTHERAPEUTIC CANDIDATE (VBI-1901). (14th November 2022) Authors: Wen, Patrick Y; Reardon, David A; Forst, Deborah; Lee, Eudocia; Daoud, Teresa; Berthoud, Tamara; Soare, Catalina; Diaz-Mitoma, Francisco; Anderson, David E; Lassman, Andrew; Iwamoto, Fabio Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 7 Page Start: vii62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Efficacy and Safety of a 3-Antigen (Pre-S1/Pre-S2/S) Hepatitis B Vaccine: Results of a Phase 3 Randomized Clinical Trial in the Russian Federation. (29th October 2020) Authors: Esaulenko, Elena V; Yakovlev, Aleksey A; Volkov, Genady A; Sukhoruk, Anastasia A; Surkov, Kirill G; Kruglyakov, Peter V; Diaz-Mitoma, Francisco Journal: Clinical infectious diseases Issue: Volume 73:Number 9(2021) Page Start: e3333 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗